Zebrafish Toxicity and Safety Assays

Rapid, Standardized Safety Triage for Early-Stage Libraries

Key Features:

• OECD 236-Aligned FET Assays --- Standardized embryo acute toxicity screens with reproducible dose-response curves, LC50/IC50 determination, and teratogenicity index scoring.
• Developmental & Reproductive Toxicity --- Multi-generational exposure assessment tracking embryonic organogenesis, larval survival, hatching rate, and fecundity endpoints.
• Morphological Phenotyping --- Standardized teratogenicity scoring across 20+ anatomical structures with blinded evaluation protocols.
• Ideal For --- Early library triage; lead prioritization before mammalian commitment; formulation safety screening; hit identification stage de-risking.

Explore the Power of Screening-Ready Safety Triage:

For virtual biotechs screening 50+ analogs, our FET panel identifies lethal and sublethal liabilities in 4--6 weeks using milligram-scale compound---data you can present to your CSO and Series B investors before committing to rodent tox. For pharma teams, the teratogenicity index and developmental window analysis provide early embryonic safety signals that cell-based assays simply cannot capture. Every screen is delivered with complete dose-response documentation and QC metrics---formatted for direct inclusion in IND packages and investor data rooms.

In Vivo Cardiac Imaging with Mechanistic Resolution

Key Features:

• Fluorescent Reporter Integration --- Real-time cardiac phenotyping using cardiac troponin and vascular reporters; quantification of heart rate, contractility, and pericardial edema.
• QT Prolongation & Arrhythmia Modeling --- Pharmacologically induced and genetically sensitized models for torsadogenic risk assessment with clinical concordance.
• High-Content Cardiac Imaging --- Automated 96-well format confocal imaging with temperature-controlled stages for long-term developmental observation.
• Ideal For --- Oncology pipeline cardiac safety; lead optimization stage hERG follow-up; combination therapy assessment; structure-toxicity relationship mapping.

Why It Matters:

Cardiotoxicity kills more oncology programs than efficacy failure. Our cardiac reporter lines turn drug-induced heart failure into observable, quantifiable light signals. When liabilities emerge, cross-referencing with our in silico ADMET predictions and medicinal chemistry capabilities enables direct feedback to your chemists---minimize the liability in the next synthesis cycle. For virtual biotechs, this means cardiac de-risking data before your next fundraising round. For pharma teams, it means IND-relevant in vivo safety narratives with statistical power.

Liver and CNS Liability Quantification in a Whole Organism

Key Features:

• Hepatocyte Reporter Models --- Hepatocyte-specific fluorescence markers for liver size quantification, bile duct morphogenesis, and hepatocyte apoptosis profiling.
• Locomotor & Neurobehavioral Batteries --- Automated larval tracking (distance, velocity, thigmotaxis) under alternating light-dark cycles; axon guidance phenotyping.
• Molecular Endpoints --- Quantitative RT-PCR profiling of stress response genes (cyp1a, sod1, caspase-3) for mechanism-of-toxicity validation.
• Ideal For --- CNS-targeted program safety de-risking; DILI early detection; neurodegenerative therapy safety windows; NMR-based pharmacometabonomics correlation studies.

How It Works:

Hepatotoxicity and neurotoxicity often manifest only in whole-organism contexts where drug metabolism and integrated physiology are intact. For biotechs developing CNS-penetrant compounds, our neurobehavioral batteries detect locomotor deficits at sub-lethal doses---signals that cell-based cultures miss entirely. For pharma teams, hepatocyte reporter data integrates directly with in vitro ADME-Tox profiling to build a cross-platform liver safety narrative for regulators.

Integrated Liability Profiling with Cross-Organ Intelligence

Key Features:

• Simultaneous Multi-Organ Assessment --- Cardiac, hepatic, and neurological endpoints quantified in individual larvae, maximizing data density per compound.
• Cross-Organ Correlation Analysis --- Statistical correlation of organ-specific liabilities to identify clean profiles versus structure-alert patterns.
• Rescue & Mechanism Screening --- Co-treatment with protective agents or pathway modulators to elucidate toxicity mechanism and identify de-risking strategies.
• Ideal For --- Final candidate selection before GLP tox; combination therapy safety assessment; hit-to-lead prioritization with limited chemical matter.

What We Offer:

Most CROs run single-organ assays in isolation. We run integrated panels that reveal how cardiac stress compounds hepatic metabolic load. For fragment-to-lead programs, our cross-organ analysis determines whether the liability is scaffold-class-wide or analog-specific---guiding medicinal chemistry resource allocation with quantitative precision. Every panel includes a priority scorecard ranking your series by multi-organ safety index.